Pharmaceutical corporations obtain unjustified patents making the drugs unaffordable to many, petitioners claim
In a latest push to make Hepatitis C drugs affordable to millions of patients, civil society groups filed five new challenges to patents in India and Argentina. These challenges were meant to alleviate the production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including sofosbuvir, daclatasvir and velpatasvir.
In India, the Initiative for Medicines, Access & Knowledge (I-MAK) together with the Delhi Network of Positive People (DNP+) and supported by Médecins Sans Frontières (MSF), filed four cases: two patent challenges on daclatasvir, one on velpatasvir and a further challenge on sofosbuvir. Separately, in Argentina, Fundación Grupo Efecto Positivo (FGEP) filed a patent opposition on sofosbuvir with support from I-MAK.
Petitioners argue that these efforts are aimed to overturn the abusive strategies of pharmaceutical corporations like Gilead who exploit flaws in the patent system to obtain unjustified patents that block generic competition.
Over 80 million people worldwide are living with Hepatitis C, and we need a wide range of combination treatments available at an affordable price. With patents blocking generic competition, treatment remains prohibitively expensive in many countries,” said Jessica Burry, pharmacist for MSF’s Access Campaign.
“Together with civil society groups, we have filed legal challenges on multiple invalid patents on three different Hepatitis C drugs,” said Tahir Amin, director of intellectual property for I-MAK. "It is time to challenge the unchecked power that pharmaceutical corporations hold through abuse of the patent system.”
“By systematically applying pressure to remove patent and regulatory barriers that stand in the way of production of more affordable generic versions of direct-acting antiviral medicines used to treat Hepatitis C, civil society and vulnerable communities have already supported the introduction of generic competition in India and Egypt, where prices dropped to below USD $300 per 12-week treatment last year,” said Leena Menghaney, head of South Asia for MSF’s Access Campaign.
Loon Gangte, regional coordinator, International Treatment Preparedness Coalition-South Asia and founder of DNP+ says, “Millions of people in India can’t afford the generic treatments strictly licensed by Gilead and BMS, and millions more people in high- and middle-income countries can’t legally purchase the generic medicines currently being produced in countries like India and Egypt. We need a sustainable supply of low-cost, quality Hepatitis C medicines to save lives and contain the disease in all countries.”
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.